3D Systems offers an asymmetric turnaround at roughly 1.0x sales, but debt, dilution, and unproven profitability keep DDD speculative.
Overview
3D Systems Corporation (NYSE: DDD) is a pioneering additive-manufacturing company serving regulated healthcare and industrial markets through hardware, proprietary materials, software, and services. Its Healthcare Solutions segment has become the larger business, exceeding 50% of revenue, while its competitive position rests on broad direct-metal and polymer capabilities and high customer switching costs created by regulatory qualification. **The turnaround is showing early operational traction but has not yet produced sustainable profitability.** Q2 2026 revenue was $94.6 million, down 0.3% year over year reported but up 1.4% organically after divestitures; Healthcare revenue rose 6.8% to $48.1 million, while Industrial revenue declined 6.7% to $46.5 million. Adjusted EBITDA improved to a $(0.8) million loss, and non-GAAP EPS of $(0.04) beat the $(0.05) consensus estimate. Cash and restricted cash reached $129.0 million, although this was supported by a dilutive $53.2 million equity offering. At roughly 1.0x–1.08x trailing sales versus a 1.82x historical median, valuation offers re-rating potential if organic growth and margins recover. Near-term catalysts include Q3 revenue guidance of $96.0–$99.0 million, the Littleton expansion, and continued adoption of Med Tech, aerospace, and NextDent products.